All articles tagged with #obesity market
A bidding war has erupted between Pfizer and Novo Nordisk for the obesity startup Metsera, with Novo valuing the company at up to $10 billion and Pfizer countering with an $8.1 billion bid. The court has allowed the bidding to continue without interference, reflecting the high stakes and interest in the lucrative obesity market, which is projected to reach $95 billion by 2030.
Novo Nordisk has made an unsolicited bid to acquire obesity-focused biotech Metsera, aiming to outbid Pfizer, which had previously announced its plan to purchase the firm. The move has sparked a bidding war in the competitive obesity market, with Metsera indicating it considers Novo's offer superior and giving Pfizer a deadline to renegotiate.
Zealand Pharma's stock surged 32% after positive trial results for its weight-loss drug, survodutide, which also showed efficacy in treating liver inflammation caused by excess fat cells. The drug has received fast-track designation from the FDA and is undergoing five Phase-3 trials for people who are overweight or obese, positioning the company as a key player in the highly lucrative obesity therapeutics market alongside competitors like Novo Nordisk and Eli Lilly.
Swiss pharmaceutical company Roche is set to acquire anti-obesity drug developer Carmot Therapeutics for $2.7 billion in cash, with the potential for an additional $400 million based on milestones. Roche aims to challenge the dominance of Novo Nordisk and Eli Lilly in the global weight loss drugs market. However, the drugs developed by Carmot are still in the early stages, and Roche's CEO expects they may not be available until 2030 or later. The acquisition will provide Roche access to Carmot's research and development portfolio, including promising drug candidates such as CT-388, a once-weekly injection, and CT-996, a once-daily oral candidate. The obesity drugs market is estimated to be worth $200 billion in the next decade, attracting new entrants while established players struggle to meet demand.
Contract drug manufacturers are investing billions of dollars to expand or build factories that fill the injection pens used for weight-loss drugs like Novo Nordisk's Wegovy. The demand for self-injection weight-loss drugs is soaring, with the obesity market estimated to be worth $100 billion within a decade. Pharmaceutical services companies are racing to secure more of the specialist work of filling the syringes used in the pens, known as fill-finish. Companies like WuXi Biologics and Catalent are expanding their pre-filled syringe capacity, while Novo's partner Thermo Fisher is converting facilities to handle pens for obesity and diabetes medicines. The race for business among contract development and manufacturing organizations (CDMOs) is accelerating, driven by the launch of new weight-loss drugs and the increasing demand for injectables.